Technical Analysis for EVG - Evgen Pharma Plc

Grade Last Price % Change Price Change
F 8.15 0.00% 0.00
EVG closed unchanged on Thursday, April 22, 2021, on 2.18 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat
Historical EVG trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
50 DMA Resistance Bearish 0.00%
Crossed Above 20 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
20 DMA Resistance Bearish 3.16%
Doji - Bullish? Reversal 3.16%
Fell Below 20 DMA Bearish 3.16%
Inside Day Range Contraction 3.16%
Down 3 Days in a Row Weakness 3.16%
20 DMA Support Bullish 0.62%
Older End-of-Day Signals for EVG ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 20 hours ago
Possible Inside Day about 20 hours ago
10 DMA Resistance about 20 hours ago
Possible Pocket Pivot about 22 hours ago
10 DMA Support about 22 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Evgen Pharma Plc Description

Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Chemistry Pharmaceutical Medicine Pipe Clinic Disease Cancer Therapy Rtt Drug Development Tumor Pharmaceutical Products Scs Breast Cancer Intensive Care Medicine Stem Cells Asos Multiple Sclerosis Neurosurgery Organic Chemistry Prostate Cancer Tumors

Is EVG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 17.0
52 Week Low 3.0
Average Volume 1,261,585
200-Day Moving Average 10.37
50-Day Moving Average 8.40
20-Day Moving Average 7.99
10-Day Moving Average 8.19
Average True Range 0.40
ADX 18.96
+DI 27.76
-DI 21.11
Chandelier Exit (Long, 3 ATRs ) 8.02
Chandelier Exit (Short, 3 ATRs ) 8.29
Upper Bollinger Band 8.75
Lower Bollinger Band 7.24
Percent B (%b) 0.6
BandWidth 18.83
MACD Line -0.05
MACD Signal Line -0.09
MACD Histogram 0.0366
Fundamentals Value
Market Cap 11.19 Million
Num Shares 137 Million
EPS -2.70
Price-to-Earnings (P/E) Ratio -3.02
Price-to-Sales 0.00
Price-to-Book 3.20
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.60
Resistance 3 (R3) 8.60 8.45 8.53
Resistance 2 (R2) 8.45 8.34 8.45 8.50
Resistance 1 (R1) 8.30 8.26 8.23 8.30 8.47
Pivot Point 8.15 8.15 8.11 8.15 8.15
Support 1 (S1) 8.00 8.04 7.93 8.00 7.83
Support 2 (S2) 7.85 7.96 7.85 7.80
Support 3 (S3) 7.70 7.85 7.78
Support 4 (S4) 7.70